Evidence map›Paper›PMID 31077946›Full record

ArticleThe Journal of surgical research2019

Anti-Claudin-1 Conjugated to a Near-Infrared Fluorophore Targets Colon Cancer in PDOX Mouse Models.

Hannah M Hollandsworth, Thinzar M Lwin, Siamak Amirfakhri, Filemoni Filemoni, Surinder K Batra, Robert M Hoffman, Punita Dhawan, Michael Bouvet

Open access · greenAbstract read
In one paragraph

Article in The Journal of surgical research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Evaluation of Ac-LysJournal of neuro-oncology · 2021
    Article
  9. Review
  10. Targeting claudins in cancer: diagnosis, prognosis and therapy.American journal of cancer research · 2021
    Review
  11. Article
  12. Claudin-1, A Double-Edged Sword in Cancer.International journal of molecular sciences · 2020
    Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Hannah M HollandsworthDepartment of Surgery, University of California San Diego, La Jolla, California; Moores Cancer Center, University of California San Diego, La Jolla, California; Department of Surgery, VA San Diego Healthcare System, San Diego, California.
Thinzar M LwinDepartment of Surgery, University of California San Diego, La Jolla, California; Moores Cancer Center, University of California San Diego, La Jolla, California; Department of Surgery, VA San Diego Healthcare System, San Diego, California.
Siamak AmirfakhriDepartment of Surgery, University of California San Diego, La Jolla, California; Moores Cancer Center, University of California San Diego, La Jolla, California; Department of Surgery, VA San Diego Healthcare System, San Diego, California.
Filemoni FilemoniDepartment of Surgery, University of California San Diego, La Jolla, California; Moores Cancer Center, University of California San Diego, La Jolla, California; Department of Surgery, VA San Diego Healthcare System, San Diego, California; AntiCancer, Inc, San Diego, California.
Surinder K BatraDepartment of Biochemistry, University of Nebraska Medical Center, Omaha, Nebraska.
Robert M HoffmanDepartment of Surgery, University of California San Diego, La Jolla, California; Moores Cancer Center, University of California San Diego, La Jolla, California; Department of Surgery, VA San Diego Healthcare System, San Diego, California; AntiCancer, Inc, San Diego, California.
Punita DhawanDepartment of Biochemistry, University of Nebraska Medical Center, Omaha, Nebraska.
Michael BouvetDepartment of Surgery, University of California San Diego, La Jolla, California; Moores Cancer Center, University of California San Diego, La Jolla, California; Department of Surgery, VA San Diego Healthcare System, San Diego, California. Electronic address: mbouvet@ucsd.edu.
University of California San Diego · USUniversity of Nebraska Medical Center · USUC San Diego Health System · US

Funding

UCSD Cancer Center Training Program in Drug DevelopmentT32CA121938 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Michael Bouvet, Dwayne G. Stupack · 2006 to 2026
$10.3M
Mastl, a novel therapeutic target in Colon CancerR21CA216746 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI DHAWAN, PUNITA · 2018 to 2019
$358k
Development of Near Infrared Fluorescence-Guided Surgical Navigation and Tumor Specific Photoimmunotherapy for Improved Outcomes for GI CancersI01BX003856 · VA · VA SAN DIEGO HEALTHCARE SYSTEM · PI BOUVET, MICHAEL · 2018 to 2022
–
BLRD VA I01 BX002086BLRD VA I01 BX003856NCI NIH HHS R21 CA216746NCI NIH HHS T32 CA121938
6 · The paper itself

Abstract

introductionClaudins are tight-junction proteins, which maintain an epithelial barrier in normal colon cells. Overexpression of Claudin-1 has been implicated for development of colon cancer. We postulated that Claudin-1 may be a useful target in near-infrared imaging and fluorescence-guided surgery.

methodsWe conjugated Claudin-1 antibody to LI-COR IR800DyeCW (Claudin-1-IRDye800CW). Western blotting of 9 human colon cancer cell lysates was performed. Animal imaging was performed with the LI-COR Pearl Trilogy Fluorescence Imaging System. A dose-response study was carried out with subcutaneous LS174T colon cancer cell line models. Increasing doses of Claudin-1-IRDye800CW via tail vein injection were administered to three groups of mice. Two groups of mice were used as controls (antibody alone, and dye alone). In vivo imaging was performed at 24, 48, and 72 h after administration of the conjugated dye. Orthotopic implantation of patient-derived tumors and cell lines was performed and peritoneal carcinomatosis models were created. After tumor growth, mice were administered Claudin-1-IRDye800CW and imaged in vivo 48 h later. The mice were euthanized and laparotomy was performed to assess internal organs and toxicity.

resultsWestern blotting revealed that all colon cancer cell lysates expressed varying amounts of Claudin-1. All tumors demonstrated strong and specific fluorescence labeling at 800 nm, even with the lowest dose of 12.5 μg of Claudin-1-IRDye800CW.

conclusionsClaudin-1 is a useful target for near-infrared antibody-based imaging for visualization of colorectal tumors for future use in fluorescence-guided surgery.

Indexed as

AnimalsAntibodies, MonoclonalBenzenesulfonatesCell Line, TumorClaudin-1ColonColonic NeoplasmsDose-Response Relationship, DrugFluorescent DyesHumansImmunoconjugatesIndolesInjections, IntravenousMaleMiceMice, NudeAntibodies, MonoclonalBenzenesulfonatesClaudin-1CLDN1 protein, humanFluorescent DyesImmunoconjugatesIndolesIRDye 800CWClaudinColon cancerFluorescence guided surgeryIRDye800CWNear infrared dye

Identifiers

PMID31077946
PMCPMC7144806
OpenAlexW2943898943

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.